Individual centers have documented the use of the Syncardia Total Artificial Heart (TAH) in adolescents with heart failure; however, the number of patients at any given center is small. Herein, we describe the worldwide experience for all patients ≤21 years old supported with the TAH between May 2005 and May 2015 (n = 43). The number of patients experiencing a positive outcome at 60, 90, and 120 days were 30 (70%), 27 (63%), and 25 (58%), respectively. Successful bridge to transplantation varied by diagnosis, but outcomes reported are similar to adults supported with the TAH or biventricular assist devices.
From the *The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; and †Cedars-Sinai Heart Institute, Los Angeles, California.
Submitted for consideration September 2016; accepted for publication in revised form December 2016.
Disclosure: D. Morales is an Instructor and consultant for Berlin Heart, Inc; Proctor, consultant, and Instructor for Syncardia, Inc.; National PI for 50/50 cc TAH FDA Trial; Consultant HeartWare Inc. F. Arabia: Instructor for Syncardia, Inc; Instructor for Heartware Inc; National PI for 50/50 cc TAH FDA Trial.
Correspondence: David L. S. Morales, The Heart Institute at Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, MLC 2004, Cincinnati, OH 45229. Email: David.Morales@cchmc.org.